Lawrence A Cohen

45390487, Sep 3, 1985

Feb 9, 1983

6/465207

Lawrence B. Cohen - Sharon MA

Jos. Cavedon Company Inc. - Woonsocket RI

C07F 700

10628717

This invention relates to novel compositions of matter which are mixed metal metallo-organic complex agents comprised of a chemically united complex aluminum moiety and tetravalent zirconium moiety. The specific process for preparing such compositions in mixed organic/aqueous media with desirable hydrolytic stability is described. Further described are compositions of matter wherein the aforementioned metallo-organics are employed as coupling agents to chemically modify the surface of fibrous and particulate inorganic substances and certain organic particulates, thereby resulting in hydrophobic, organophilic fibers and particles having improved rheological properties which facilitate higher filler or fiber loading levels, e. g. in plastics and resins, and serve to enhance the physical properties of composite articles and coatings formed therewith.

61401110, Oct 31, 2000

Jun 7, 1995

8/486858

Isabelle Riviere - Boston MA
Lawrence K. Cohen - Oakland CA
Brad Guild - Concord MA
Lori F. Rafield - San Francisco CA
Paul Robbins - Mt. Lebanon PA
Richard C. Mulligan - Lincoln MA

Whitehead Institute for Biomedical Research - Cambridge MA
Cell Genesys, Inc. - Foster City CA

C12N 1563
C12N 1585
C12N 1582
A61K 4800

4353201

Retroviral vectors are disclosed which include an insertion site for genes of interest and are capable of expressing high levels of the protein derived from the genes of interest in a wide variety of transfected cell types. Also disclosed are retroviral vectors lacking a selectable marker, thus rendering them suitable for human gene therapy in the treatment of a variety of disease states without the co-expression of a marker product, such as an antibiotic. These retroviral vectors are especially suited for use in certain packaging cell lines.

45390495, Sep 3, 1985

Mar 22, 1983

6/478043

Lawrence B. Cohen - Sharon MA

Jos. Cavedon Co., Inc. - Woonsocket RI

C07F 700

10628717

This invention relates to novel compositions of matter which are mixed metal metallo-organic complex agents comprised of a chemically united complex aluminum moiety and a tetravalent zirconium moiety. The specific process for preparing such compositions in organic/solvent media with desirable hydrolytic stability is described. Further described are compositions of matter wherein the aforementioned metallo-organics are employed to chemically modify the surface of fibrous and particulate inorganic substances and certain organic particulates, thereby resulting in hydrophobic, organophilic fibers and particles having improved rheological properties which facilitate higher filler (fiber) loading levels and serve to enhance the physical properties of composite articles and coatings formed therewith.

47646322, Aug 16, 1988

Jan 7, 1986

6/816814

Lawrence B. Cohen - Sharon MA

Cavedon Chemical Company, Inc. - Woonsocket RI

C07F 506
C07F 700

556 27

This invention relates to novel compositions of matter which are multifunctional amino zirconium aluminum metallo organic complexes which are comprised of a chemically united complex aluminum moiety, a tetravalent zirconium moiety, and a multifunctional amino acid wherein the acid is chemically bound to both the aluminum and zirconium centers. Such compositions are useful in promoting adhesion of adhesives, sealants, and coatings to metal, rubber, glass, plastic, coatings, and wood thereby enhancing strength properties and prolonging useful service life when such products are exposed to aggressive environments. Futher described is the specific process for the preparing of such compositions in organic media with desirable stability of the metal centers toward polymerization and related hydrolysis.

60013508, Dec 14, 1999

Jun 7, 1995

8/488420

Richard C. Mulligan - Lincoln MA
Lawrence K. Cohen - Oakland CA
Louis K. Birinyi - Boston MA
James M. Wilson - Ann Arbor MI

A61K 4800
C12N 510

424 9321

Endothelial cells transduced with genetic material encoding a polypeptide or protein of interest and, optionally, a selectable marker, as well as methods for making and using the transduced endothelial cells are disclosed. Such endothelial cells are useful in improving the performance of vascular grafts and in delivering the encoded polypeptide or protein, such as an enzyme, a hormone, a receptor or a drug, to an individual.

43412130, Jul 27, 1982

Aug 13, 1981

6/292374

Lawrence B. Cohen - Sharon MA

The Kendall Co. - Boston MA

A41B 1302

128284

Nonwoven fabrics are bonded by a binding agent which comprises an aqueous dispersion of an organic polymer coupled to an inorganic filler by means of an organosilane or organotitanate coupling agent. Such fabrics possess properties which render them exceptionally suitable for use as top sheets for disposable diapers and the like.

50932586, Mar 3, 1992

Aug 26, 1988

7/237285

Lawrence K. Cohen - Brighton MA
Dennis L. Panicali - Acton MA

Therion Biologics Corporation - Cambridge MA

C12N 701
C12N 1586
C12N 1539
A61K 39295

4352351

Recombinant fowlpox virus (FPV) capable of expressing immunogenic proteins of fowl pathogens are described. The FPV express DNA of the pathogen under the direction of FPV promoters. The recombinant FPV provide live vaccines for poultry and other animals.

56747225, Oct 7, 1997

May 25, 1994

8/249092

Richard C. Mulligan - Lincoln MA
Lawrence K. Cohen - Oakland CA
Lori F. Rafield - San Fransisco CA
Louis K. Birinyi - Boston MA
Allan D. Callow - St. Louis MO
James M. Wilson - Ann Arbor MI

Somatix Therapy Corporation - Alameda CA
Whitehead Institute For Biomedical Research - Cambridge MA
Brigham & Womens Hospital - Boston MA
Howard Hughes Medical Institute - Bethesda MD
New England Medical Center Hospitals - Boston MA

C12N 1586
C12N 516
A61F 204
A61F 206

4351723

Endothelial cells transduced with genetic material encoding a polypeptide or protein of interest and, optionally, a selectable marker, as well as methods for making and using the transduced endothelial cells are disclosed. Such endothelial cells are useful in improving the performance of vascular grafts and in delivering the encoded polypeptide or protein, such as an enzyme, a hormone, a receptor or a drug, to an individual.